Is Himax’s New AI Drone Imaging Push Reshaping the Investment Case for Himax Technologies (HIMX)?

• Himax Technologies announced that its subsidiary Liqxtal Technology, together with iCatch Technology, will showcase a joint AI-powered drone imaging solution at CES 2026, combining long-range electro-optical and thermal infrared cameras with an edge AI computing platform for applications such as aerial photography, security, and industrial inspection.
• This move highlights Himax’s push to extend its imaging and AI capabilities beyond automotive and consumer electronics into drone-based surveillance and inspection markets, potentially broadening future use cases for its sensing and vision technologies.
• Next, we’ll examine how this AI drone imaging collaboration may influence Himax’s broader AI sensing and optical solutions investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Himax Technologies Investment Narrative Recap

To own Himax, I think you need to believe its core display and sensing business can transition toward higher value AI-driven applications while stabilizing margins after recent earnings pressure. The new AI drone imaging showcase looks more like a small, early-stage extension of its vision portfolio than a near-term financial catalyst, and it does not meaningfully change the biggest near-term risk around uneven demand and limited visibility across automotive and consumer end markets.

The CES 2026 drone solution, which pairs Liqxtal’s long-range electro-optical and thermal cameras with iCatch’s edge AI platform, ties directly into Himax’s broader push in WiseEye AI and optical technologies highlighted at recent healthcare and security events. For me, it reinforces the story that management is trying to seed multiple AI sensing use cases, even as current results still depend heavily on more mature display-driver segments that are seeing revenue softness and margin pressure.

Yet while these AI initiatives are encouraging, investors should also be aware of the risk that Himax’s revenue remains concentrated in cyclically sensitive automotive and consumer electronics...

Read the full narrative on Himax Technologies (it's free!)

Himax Technologies’ narrative projects $1.1 billion revenue and $139.3 million earnings by 2028. This requires 7.4% yearly revenue growth and a $65.1 million earnings increase from $74.2 million today.

Uncover how Himax Technologies' forecasts yield a $8.54 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Seven members of the Simply Wall St Community currently see fair value for Himax anywhere between about US$1.87 and US$91.18 per share, reflecting sharply different growth assumptions. When you set those views against the company’s reliance on still-early AI and optical products to offset macro and customer demand uncertainty, it becomes clear why you might want to compare several perspectives before deciding how this fits in your portfolio.

Explore 7 other fair value estimates on Himax Technologies - why the stock might be a potential multi-bagger!

Build Your Own Himax Technologies Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Himax Technologies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Himax Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Himax Technologies' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Outshine the giants: these 24 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com